Boostrix

In May 2020, a class-action lawsuit was filed against GlaxoSmithKline for allegedly falsely advertising the medication Boostrix in what has been referred to as “The Big Bad Cough” advertising campaign. Plaintiffs claim that the company falsely advertises that Boostrix makes users less likely to become infected with and transmit whooping cough when, according to the complaint, the medicine generates antibodies to only five of the thousands of the antigens of whooping cough, which means people who take Boostrix may still become infected and transmit whooping cough even if they are showing few or no symptoms. (DeCostanzo et al v. GlaxoSmithKline PLC, Case No. 20-cv-2284, E.D.N.Y.)

For more of TINA.org’s coverage of medicine, click here.

Print Friendly, PDF & Email

Tags:



Leave a Reply

Back to Top ↑
  • Search Class-Action Tracker



  • Recent Class Actions

  • The Class-Action Tracker is intended to notify consumers about false advertising class-action lawsuits filed around the country, but does not necessarily reflect TINA.org’s opinion with respect to the lawsuits or disposition of the cases

  • Sign Up for E-mail Updates